126 related articles for article (PubMed ID: 27348300)
1. Occurrence of JAK2V617F mutation in previously triple negative essential thrombocythemia.
Benetatos L
Leuk Lymphoma; 2017 Feb; 58(2):503-504. PubMed ID: 27348300
[No Abstract] [Full Text] [Related]
2. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia.
Kittur J; Knudson RA; Lasho TL; Finke CM; Gangat N; Wolanskyj AP; Li CY; Wu W; Ketterling RP; Pardanani A; Tefferi A
Cancer; 2007 Jun; 109(11):2279-84. PubMed ID: 17440984
[TBL] [Abstract][Full Text] [Related]
3. Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis.
Yönal İ; Dağlar-Aday A; Akadam-Teker B; Yılmaz C; Nalçacı M; Yavuz AS; Sargın FD
Turk J Haematol; 2016 Jun; 33(2):94-101. PubMed ID: 25913509
[TBL] [Abstract][Full Text] [Related]
4. A case of JAK2V617F-positive essential thrombocythemia where allele burden was reduced by a PD-1 inhibitor.
Hara R; Kawada H; Kikuti YY; Kikkawa E; Harada K; Aoyama Y; Ogiya D; Toyosaki M; Suzuki R; Machida S; Ohmachi K; Onizuka M; Ogawa Y; Masuda R; Iwazaki M; Nakamura N; Ando K
Int J Hematol; 2021 Apr; 113(4):606-610. PubMed ID: 33389657
[TBL] [Abstract][Full Text] [Related]
5. Essential differences in clinical and bone marrow features in BCR/ABL-positive thrombocythemia compared to thrombocythemia in the BCR/ABL-negative myeloproliferative neoplasms essential thrombocythemia and polycythemia vera.
Michiels JJ; Pich A; De Raeve H; Gadisseur A
Acta Haematol; 2015; 133(1):52-5. PubMed ID: 25116159
[No Abstract] [Full Text] [Related]
6. JAK2V617F mutation and allele burden are associated with distinct clinical and morphological subtypes in patients with essential thrombocythaemia.
Pich A; Riera L; Beggiato E; Nicolino B; Godio L; Campisi P; Sismondi F; di Celle PF
J Clin Pathol; 2012 Oct; 65(10):953-5. PubMed ID: 22718845
[No Abstract] [Full Text] [Related]
7. Essential Thrombocythemia Associated With Germline JAK2 G571S Variant and Somatic CALR Type 1 Mutation.
Panovska-Stavridis I; Eftimov A; Ivanovski M; Pivkova-Veljanovska A; Cevreska L; Hermouet S; Dimovski AJ
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):e55-7. PubMed ID: 27009537
[No Abstract] [Full Text] [Related]
8. JAK2V617F mutation is associated with special alleles in essential thrombocythemia.
Hsiao HH; Liu YC; Tsai HJ; Lee CP; Hsu JF; Lin SF
Leuk Lymphoma; 2011 Mar; 52(3):478-82. PubMed ID: 21281225
[TBL] [Abstract][Full Text] [Related]
9. [Correlations of jak2v617f mutation with clinical and laboratory findings in primary thrombocythemia patients].
Xia J; Xu W; Zhang SJ; Sun XM; Duan LM; Li WD; Qiou HX; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr; 16(2):416-20. PubMed ID: 18426677
[TBL] [Abstract][Full Text] [Related]
10. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
[TBL] [Abstract][Full Text] [Related]
11. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
12. Dysplasia of all granulocyte lineages in myelodysplastic evolution of essential thrombocythemia.
Bain BJ; Garnett C; Deplano S; Naresh K; Kanfer E
Am J Hematol; 2013 May; 88(5):426. PubMed ID: 23460316
[No Abstract] [Full Text] [Related]
13. Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia.
Shirane S; Araki M; Morishita S; Edahiro Y; Sunami Y; Hironaka Y; Noguchi M; Koike M; Sato E; Ohsaka A; Komatsu N
Int J Hematol; 2015 Feb; 101(2):148-53. PubMed ID: 25522845
[TBL] [Abstract][Full Text] [Related]
14. Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Leukemia; 2008 Jan; 22(1):194-5. PubMed ID: 17625603
[No Abstract] [Full Text] [Related]
15. The impact of JAK2V617F mutation on different types of thrombosis risk in patients with essential thrombocythemia: a meta-analysis.
Qin Y; Wang X; Zhao C; Wang C; Yang Y
Int J Hematol; 2015 Aug; 102(2):170-80. PubMed ID: 25997869
[TBL] [Abstract][Full Text] [Related]
16. The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the "early" prepolycythemic phase of polycythemia vera and essential thrombocythemia.
Gianelli U; Iurlo A; Vener C; Moro A; Fermo E; Bianchi P; Graziani D; Radaelli F; Coggi G; Bosari S; Deliliers GL; Zanella A
Am J Clin Pathol; 2008 Sep; 130(3):336-42. PubMed ID: 18701405
[TBL] [Abstract][Full Text] [Related]
17. Correlative study between the JAK2V617F mutation and thrombosis in patients with myeloproliferative neoplasm.
Li ZC; Fu HJ; Wang ZM; Yang S; Xu HZ
Genet Mol Res; 2016 Aug; 15(3):. PubMed ID: 27706633
[TBL] [Abstract][Full Text] [Related]
18. A novel Janus Kinase 2 mutation involving 14th intron splicing region in a patient with essential thrombocythemia.
Sun X; Xu Z; Xie L; Lai R; Zhu X; Zhang W; Xie W
Leuk Lymphoma; 2009 Dec; 50(12):2089-91. PubMed ID: 20001246
[No Abstract] [Full Text] [Related]
19. Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera.
Ganly P; Hanrahan V; Baker B; Romeril K
Am J Hematol; 2007 Jan; 82(1):80-2. PubMed ID: 16924638
[TBL] [Abstract][Full Text] [Related]
20. Absence of FTL3 mutations in patients with JAK2V617F mutation negative essential thrombocythemia.
Medeiros BC; Zhang T; Lipton JH; Kamel-Reid S
Am J Hematol; 2007 Apr; 82(4):293-4. PubMed ID: 17013813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
